Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 19 studies | 33% ± 13% | |
peripheral blood | 19 studies | 42% ± 12% | |
brain | 19 studies | 30% ± 16% | |
intestine | 9 studies | 29% ± 12% | |
eye | 9 studies | 27% ± 11% | |
kidney | 8 studies | 31% ± 10% | |
adipose | 5 studies | 33% ± 11% | |
lymph node | 5 studies | 38% ± 7% | |
breast | 5 studies | 28% ± 7% | |
liver | 5 studies | 42% ± 15% | |
pancreas | 4 studies | 42% ± 26% | |
bone marrow | 4 studies | 36% ± 13% | |
heart | 4 studies | 22% ± 3% | |
uterus | 4 studies | 43% ± 13% | |
placenta | 3 studies | 26% ± 6% | |
skin | 3 studies | 22% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 26723.67 | 21 / 21 | 100% | 86.34 | 504 / 504 |
breast | 100% | 33397.16 | 459 / 459 | 100% | 129.71 | 1118 / 1118 |
esophagus | 100% | 24499.28 | 1445 / 1445 | 100% | 117.97 | 183 / 183 |
lung | 100% | 28784.88 | 578 / 578 | 100% | 99.69 | 1155 / 1155 |
uterus | 100% | 38995.21 | 170 / 170 | 100% | 99.42 | 459 / 459 |
intestine | 100% | 31540.82 | 966 / 966 | 100% | 88.07 | 526 / 527 |
prostate | 100% | 28938.60 | 245 / 245 | 100% | 91.27 | 501 / 502 |
ovary | 100% | 38505.09 | 180 / 180 | 100% | 69.65 | 429 / 430 |
stomach | 100% | 23064.18 | 359 / 359 | 100% | 86.27 | 285 / 286 |
thymus | 100% | 31206.89 | 653 / 653 | 100% | 106.43 | 602 / 605 |
pancreas | 100% | 20068.92 | 328 / 328 | 99% | 99.70 | 177 / 178 |
kidney | 100% | 19597.65 | 89 / 89 | 99% | 84.37 | 890 / 901 |
brain | 98% | 13844.72 | 2591 / 2642 | 100% | 96.00 | 705 / 705 |
adrenal gland | 100% | 27462.44 | 258 / 258 | 98% | 64.52 | 225 / 230 |
skin | 100% | 26844.61 | 1809 / 1809 | 97% | 96.39 | 457 / 472 |
liver | 100% | 13471.76 | 226 / 226 | 95% | 50.52 | 387 / 406 |
adipose | 100% | 30770.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 29064.19 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 95.74 | 29 / 29 |
muscle | 100% | 17193.12 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 45596.84 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 90.62 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 31.93 | 1 / 1 |
heart | 99% | 14535.21 | 851 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 91% | 18215.34 | 849 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 86% | 49.22 | 69 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0006338 | Biological process | chromatin remodeling |
GO_1903241 | Biological process | U2-type prespliceosome assembly |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0008380 | Biological process | RNA splicing |
GO_0045945 | Biological process | positive regulation of transcription by RNA polymerase III |
GO_0045943 | Biological process | positive regulation of transcription by RNA polymerase I |
GO_0000245 | Biological process | spliceosomal complex assembly |
GO_0000375 | Biological process | RNA splicing, via transesterification reactions |
GO_0005686 | Cellular component | U2 snRNP |
GO_0005730 | Cellular component | nucleolus |
GO_0005681 | Cellular component | spliceosomal complex |
GO_0110016 | Cellular component | B-WICH complex |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0071005 | Cellular component | U2-type precatalytic spliceosome |
GO_0005684 | Cellular component | U2-type spliceosomal complex |
GO_0034693 | Cellular component | U11/U12 snRNP |
GO_0071004 | Cellular component | U2-type prespliceosome |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_0005689 | Cellular component | U12-type spliceosomal complex |
GO_0005634 | Cellular component | nucleus |
GO_0003729 | Molecular function | mRNA binding |
GO_1990935 | Molecular function | splicing factor binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | SF3B1 |
Protein name | Splicing factor 3B subunit 1 (Pre-mRNA-splicing factor SF3b 155 kDa subunit) (SF3b155) (Spliceosome-associated protein 155) (SAP 155) Splicing factor 3b subunit 1 SF3B1 protein |
Synonyms | SAP155 |
Description | FUNCTION: Component of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs . The 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA branch-site adenosine, the nucleophile for the first step of splicing . Within the 17S U2 SnRNP complex, SF3B1 is part of the SF3B subcomplex, which is required for 'A' complex assembly formed by the stable binding of U2 snRNP to the branchpoint sequence in pre-mRNA . Sequence independent binding of SF3A and SF3B subcomplexes upstream of the branch site is essential, it may anchor U2 snRNP to the pre-mRNA . May also be involved in the assembly of the 'E' complex . Also acts as a component of the minor spliceosome, which is involved in the splicing of U12-type introns in pre-mRNAs . Together with other U2 snRNP complex components may also play a role in the selective processing of microRNAs (miRNAs) from the long primary miRNA transcript, pri-miR-17-92 (By similarity). . |
Accessions | ENST00000414174.1 O75533 F8WC19 A0PJH5 ENST00000414963.2 [O75533-2] Q32Q20 A0A494C1M2 ENST00000652738.1 B4DGZ4 Q7Z497 A0JLT9 ENST00000424674.1 H7C341 ENST00000409915.8 [O75533-2] ENST00000487698.5 ENST00000335508.11 [O75533-1] ENST00000652026.1 |